Xencor to Participate at Upcoming Investor Conferences
Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and autoimmune disease treatments, has announced its participation in two major healthcare investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
2025 Wells Fargo Healthcare Conference
Date: Wednesday, September 3, 2025
Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT
-
Cantor Global Healthcare Conference 2025
Date: Thursday, September 4, 2025
Presentation Time: 8:00 a.m. ET / 5:00 a.m. PT
Live webcasts of the presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250827152752/en/
Charles Liles
cliles@xencor.com
(626) 737-8118
Source: Xencor, Inc.